Safe handling of oral antineoplastic medications: Focus on targeted therapeutics in the home setting

Winkler GC Barle EL Galati G . Functional differentiation of cytotoxic cancer drugs and targeted cancer therapeutics. Regul Toxicol Pharmacol 2014; 70: 46–53.

Modjtahedi H Ali S Essapen S . Therapeutic application of monoclonal antibodies in cancer: advances and challenges. Br Med Bull 2012; 104: 41–59.

Izar B Rotow J Gainor J . Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer. Pharmacol Rev 2013; 65: 1351–1395.

Levitzki A . Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxicol 2013; 53: 161–185.

Buffery D . The 2015 oncology drug pipeline: innovation drives the race to cure cancer. Am Health Drug Benefits 2015; 8: 216–222.

Chu E De Vita VT Jr . Physicians' cancer chemotherapy drug manual 2015, Burlington, MA: Jones & Bartlett Learning, 2015.

Connor TH McDiarmid MA . Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin 2006; 56: 354–365.

Friese CR Himes-Ferris L Frasier MN . Structures and processes of care in ambulatory oncology settings and nurse-reported exposure to chemotherapy. BMJ Qual Saf 2012; 21: 753–759.

Lawson CC Rocheleau CM Whelan EA . Occupational exposures among nurses and risk of spontaneous abortion. Am J Obstet Gynecol 2012; 206: e1–e8.

Connor TH Lawson CC Polovich M . Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings. JOEM 2014; 56: 901–910.

Connor TH DeBord G Pretty JR . Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers. J Occup Environ Med 2010; 52: 1019–1027.

Yuki M Sekine S Takase K . Exposure of family members to antineoplastic drugs via excreta of treated cancer patients. J Oncol Pharm Pract 2012; 19: 208–217.

Yuki M Takase K Sekine S . Evaluation of surface contamination with cyclophosphamide in the home setting of outpatients on cancer chemotherapy. J Nurs Educ Pract 2014; 4: 16–23.

Bressolle F Jacquet JM Galtier M . Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva. Cancer Chemother Pharmacol 1992; 30: 215–218.

Takehiko M Rie Y Tomonori N . Excretion of cytosine arabinoside in saliva after its administration at high doses. Anticancer Drugs 2006; 17: 597–598.

Madsen ES Larsen H . Excretion of mutagens in sweat from humans treated with anti-neoplastic drugs. Cancer Lett 1988; 40: 199–202.

Mader RM Rizovski B Steger GG . Exposure of oncologic nurses to methotrexate in the treatment of osteosarcoma. Arch Environ Health 1996; 51: 310–314.

Pichini S Zuccaro P Pacifici GM . Drugs in semen. Clin Pharm 1994; 26: 356–373.

Cass Y Musgrave CF . Guidelines for the safe handling of excreta contaminated by cytotoxic agents. Am J Health Syst Pharm 1992; 49: 1957–1958.

National Institute for Occupational Safety and Health. NIOSH Alert: preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings, Cincinnati, OH: Department of Health and Human Services, NIOSH, 2004. NIOSH publication no. 2004–165.

American Society of Health-Systems Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health Syst Pharm 2006; 63: 1172–1193.

International Society of Oncology Pharmacy Practitioners. Standards of practice: safe handling of cytotoxics. J Oncol Pharm Pract 2007; 13(Suppl): 1–81.

Polovich M Bolton DL Eisenberg S . Safe handling of hazardous drugs, 2nd ed. Pittsburgh: Oncology Nursing Society, 2011.

Polovich M Olsen M LeFebvre K . Chemotherapy biotherapy guidelines and recommendations for practice, 4th ed. Pittsburgh: Oncology Nursing Society, 2014.

Weingart SN Brown E Bach PB . NCCN task force report: oral chemotherapy. J Natl Compr Canc Netw 2008; 6: S1–S14.

Goodin S Griffith N Chen B . Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. J Oncol Practice 2011; 7: 7–12.

Patel JD Krilov L Adams S . Clinical cancer advances 2013: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 2014; 32: 129–160.

Masters GA Krilov L Bailey HB . Clinical cancer advances 2015: annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol 2015; 33: 786–809.

Goldman JM . How I treat chronic myeloid leukemia in the imatinib era. Blood 2007; 110: 2828–2837.

Kim DY Joo YD Lim SN . Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood 2015; 126: 746–756.

Hojjat-Farsangi M . Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. Int J Mol Sci 2014; 15: 13768–13801.

Fong PC Boss DS Yap TA . Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123–134.

Lheureux S Oza A . Olaparib for the treatment of ovarian cancer. Expert Opin Orphan Drugs 2014; 2: 497–508.

Eisenberg BL Trent JC . Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. Int J Cancer 2011; 129: 2533–2544.

Jabbour E Kantarjian H Cortes J . Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk 2015; 15: 323–334.

Gandhi L Jänne PA . Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res 2012; 18: 3737–3742.

Li S Qi X Huang Y . Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer. Clin Lung Cancer 2015; 16: 86–91.

Furman RR Sharman JP Coutre SE . Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997–1007.

Jaglowski SM Jones JA Nagar V . Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood 2015; 126: 842–850.

ASHP . Technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 1900; 47: 1033–1049.

National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2014, Cincinnati, OH: U.S. Department of Health and Human Services, NIOSH, 2014. NIOSH publication no. 2014–138.

Guidance for industry S9 nonclinical evaluation for anticancer pharmaceuticals. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), March 2010, www.fda.gov/downloads/Drugs/…/Guidances/ucm085389.pdf (accessed 22 February 2016).

Mandala M Massi D De Giorgi V . Cutaneous toxicities of BRAF inhibitors: clinical and pathological challenges and call to action. Crit Rev Oncol Hematol 2013; 88: 318–337.

Lacouture ME O'Reilly K Rosen N . Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern? J Clin Oncol 2012; 30: 329–330.

Fischer A Choi JN Lacouture ME . Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep 2013; 15: 249–259.

Mohan SV Chang AL . Management of cutaneous and extracutaneous side effects of smoothened inhibitor therapy for advanced basal cell carcinoma. Clin Cancer Res 2015; 21: 2677–2683.

Brown JR Barrientos JC Barr PM . The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood 2015; 125: 2915–2922.

Tsimberidou AM Wen S McLaughlin P . Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 2009; 27: 904–910.

Kaufman B Shapira-Frommer R Schmutzler RK . Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33: 244–250.

Ito S. PARP inhibition induces genomic instability in normal human cells. Abstract PR-10. In: Proceedings of the AACR-NCI-EORTC international conference: molecular targets and cancer therapeutics, San Francisco, CA, Philadelphia, PA: AACR; Mol Cancer Ther 2011: 10(11 Suppl); Abstract nr PR–10.

Do K Chen AP . Molecular pathways: targeting PARP in cancer treatment. Clin Cancer Res 2013; 19: 977–984.

Scott CL Swisher EM Kaufmann SH . Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol 2015; 33: 1397–1406.

Curtin NJ Szabo C . Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med 2013; 34: 1217–1256.

Lord CJ Tutt ANJ Ashworth A . Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med 2015; 66: 455–470.

Food and Drug Administration. Pregnancy and lactation labeling final rule, www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm (2014). (accessed 22 February 2016).

Weisz B Meirow D Schiff E . Impact and treatment of cancer during pregnancy. Exper Rev Anticancer Ther 2004; 4: 889–991.

Muslim M Goldberg J Hageboutros A Chemo and radiation therapy during pregnancy. In: Barnea ER Jauniaux E Schwartz PE (eds). Cancer and pregnancy, London: Springer, 2001, pp. 108–118.

Cardonick E Iacobucci A . Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5: 283–291.

Loibl S von Minckwitz G Gwyn K . Breast carcinoma during pregnancy: international recommendations from an expert meeting. Cancer 2006; 106: 237–246.

Peccatori FA Azim HA Jr Orecchia R . Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6): vi160–170.

Shoshan MC Linder S . Target specificity and off-target effects as determinants of cancer drug efficacy. Expert Opin Drug Metab Toxicol 2008; 4: 273–280.

Dy GK Adjei AA . Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 2013; 63: 249–279.

Blagosklonny MV . Teratogens as anti-cancer drugs. Cell Cycle 2005; 11: 1518–1521.

Apperley J . CML in pregnancy and childhood. Best Pract Res Clin Haematol 2009; 22: 455–474.

El Gendy MM Kandil AM Helal MA . The teratogenic effects of imatinib mesylate on rat fetuses. Toxicol Rep 2015; 2: 654–663.

Ai J Tiu RV . Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations. Ther Adv Hematol 2014; 5: 107–120.

Brave M Goodman V Kaminskas E . Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008; 14: 352–359.

Palani R Milojkovic D Apperley JF . Managing pregnancy in chronic myeloid leukaemia. Ann Hematol 2015; 94(Suppl 2): S167–S176.

He K Lago MW Iyer RA . Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metab Dispos 2008; 36: 2564–2570.

Ferdinand R Mitchell SA Batson S . Treatments for chronic myeloid leukemia: a qualitative systematic review. J Blood Med 2012; 3: 51–76.

Deininger M Buchdunger E Druker BJ . The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640–2653.

Fava C Kantarjian H Cortes J . Development and targeted use of nilotinib in chronic myeloid leukemia. Drug Des Devel Ther 2008; 2: 233–243.

Hochhaus A Kantarjian H . The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol 2013; 139: 1971–1984.

Xu X Bringas P Jr Soriano P . PDGFR-alpha signaling is critical for tooth cusp and palate morphogenesis. Dev Dyn 2005; 232: 75–84.

Sun T Jayatilake D Afink GB . A human YAC transgene rescues craniofacial and neural tube development in PDGFR alpha knockout mice and uncovers a role for PDGFR alpha in prenatal lung growth. Development 2000; 127: 4519–4529.

Galanis A Levis M . Inhibition of c-Kit by tyrosine kinase inhibitors. Haematologica 2015; 100: e77–e79.

Broudy VC . Stem cell factor and hematopoiesis. Blood 1997; 90: 1345–1364.

Mitsunari M Harada T Tanikawa M . The potential role of stem cell factor and its receptor c-kit in the mouse blastocyst implantation. Mol Hum Reprod 1999; 5: 874–879.

Gotink KJ Verheul HM . Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 2010; 13: 1–14.

Haigh JJ . Role of VEGF in organogenesis. Organogenesis 2008; 4: 247–256.

Del Moral PM Sala FG Tefft D . VEGF-A signaling through Flk-1 is a critical facilitator of early embryonic lung epithelial to endothelial crosstalk and branching morphogenesis. Dev Biol 2006; 290: 177–188.

Patyna S Haznedar J Morris D . Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol 2009; 86: 204–213.

Morinello E Pignatello M Villabruna L . Embryofetal development study of vismodegib, a hedgehog pathway inhibitor, in rats. Birth Defects Res B Dev Reprod Toxicol 2014; 101: 135–143.

Cohen MM Jr . Holoprosencephaly: clinical, anatomic, and molecular dimensions. Birth Defects Res A Clin Mol Teratol 2006; 76: 658–673.

Berveiller P Andreoli A Mir O . A dramatic fetal outcome following transplacental transfer of dasatinib. Anticancer Drugs 2012; 23: 754–757.

Kroll T Ames MB Pruett JA . Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib. Leuk Lymphoma 2010; 51: 1751–1753.

Pye SM Cortes J Ault P . The effects of imatinib on pregnancy outcome. Blood 2008; 111: 5505–5508.

Abruzzese E, Trawinska MM, Perrotti AP, et al. Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis 2014; 6(1): e2014028, www.ncbi.nlm.nih.gov/pmc/articles/PMC4010610/(accessed 22 February 2016).

Stopfer P Marzin K Narjes H . Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol 2012; 69: 1051–1061.

European Medicines Agency. Gilotrif: CHMP assessment report, www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/002280/WC500152394.pdf (2013, accessed 25 July 2013).

Engle JA Kolesar JM . Afatinib: a first-line treatment for selected patients with metastatic non-small-cell lung cancer. Am J Health Syst Pharm 2014; 71: 1933–1938.

ChenY Tortorici MA Garrett M . Clinical pharmacology of axitinib. Clin Pharmacokinet 2013; 52: 713–725.

Smith BJ Pithavala Y Bu HZ . Pharmacokinetics, metabolism, and excretion of [14C] axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans. Drug Metab Dispos 2014; 42: 918–931.

European Medicines Agency. Bosulif: CHMP assessment report, www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/002373/WC500141745.pdf (2013, accessed 17 January 2013).

Doan V Wang A Prescott H . Bosutinib for the treatment of chronic myeloid leukemia. Am J Health Syst Pharm 2015; 72: 439–447.

Karras S Pontikides N Krassas GE . Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer. Expert Opin Drug Metab Toxicol 2013; 9: 507–515.

Lacy S Hsu B Miles D . Metabolism and disposition of cabozantinib in healthy male volunteers and pharmacologic characterization of its major metabolites. Drug Metab Dispos 2015; 43: 1190–1207.

European Medicines Agency. Zykadia: CHMP assessment report, www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/003819/WC500187506.pdf (2015, accessed 26 February 2015).

Cooper MR Chim H Chan H . Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer. Ann Pharmacother 2015; 49: 107–112.

Choo E Takahashi R Rooney I . Assessing human absorption, metabolism, routes of excretion and the contribution of intestinal metabolism to the oral clearance of cobimetinib, a MEK inhibitor. Proceedings of the AACR-NCI-EORTC international conference: molecular targets and cancer therapeutics. Mol Cancer Ther 2013; 12(11 Suppl): abstract B160.

Takahashi RH Choo EF Ma S . Absorption, metabolism, excretion, and the contribution of intestinal metabolism to the oral disposition of [14C] cobimetinib, a MEK inhibitor, in humans. Drug Metab Dispos 2016; 44: 28–39.

European Medicines Agency. Xalkori: CHMP assessment report, www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002489/WC500134761.pdf (2012, accessed 19 July 2012).

Timm A Kolesar JM . Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm 2013; 70: 943–947.

Malik SM Maher VE Bijwaard KE . U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res 2014; 20: 2029–2034.

Bershas DA Ouellet D Mamaril-Fishman DB . Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation. Drug Metab Dispos 2013; 41: 2215–2224.

Trinh VA Davis JE Anderson JE . Dabrafenib therapy for advanced melanoma. Ann Pharmacother 2014; 48: 519–529.

Christopher LJ Cui D Wu C . Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 2008; 36: 1357–1364.

Lu JF Eppler SM Wolf J . Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small-cell lung cancer. Clin Pharmacol Ther 2006; 80: 136–145.

Ling J Johnson KA Miao Z . Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 2006; 34: 420–426.

O’Donnell A Faivre S Burris HA . Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1588–1595.

Grgic T Mis L Hammond JM . Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma. Ann Pharmacother 2011; 45: 78–83.

Swaisland HC Smith RP Laight A . Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet 2005; 44: 1165–1177.

McKillop D Partridge EA Hutchison M . Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica 2004; 34: 917–934.

Brown JR . Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. Leuk Lymphoma 2014; 55: 263–269.

Scherrrs E Leeclercq L de Jong J . Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos 2015; 43: 289–297.

Jin F Robeson M Zhou H . Pharmacokinetics, metabolism and excretion of idelalisib [ASH abstract]. Blood 2013; 122: 5570–5570.

European Medicines Agency. Zydelig: CHMP assessment report, www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003843/WC500175379.pdf (2014, accessed 24 July 2014).

Shah A Mangaonkar A . Idelalisib: a novel PI3Kδ inhibitor for chronic lymphocytic leukemia. Ann Pharmacother 2015; 49: 1162–1170.

Peng B Lloyd P Schran H . Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44: 879–894.

Gschwind HP Pfaar U Waldmeier F . Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 2005; 33: 1503–1512.

Medina PJ Goodin S . Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008; 30: 1426–1447.

Castellino S O’Mara M Koch K . Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity. Drug Metab Dispos 2012; 40: 139–150.

Yamada K Yamamoto N Yamada Y . Phase I dose escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 2011; 17: 2528–3257.

Dubbelman AC Rosing H Nijenhuis C . Pharmacokinetics and excretion of 14C-lenvatinib in patients with advanced solid tumors or lymphomas. Invest New Drugs 2015; 33: 233–240.

Deremer DL Ustun C Natarajan K . Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 2008; 30: 1956–1975.

Hazarica M Jiang X Liu Q . Tasigna for chronic and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008; 14: 5325–5331.

Stopfer P Rathgen K Bischoff D . Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica 2011; 41: 297–311.

Dhillon S . Nintedanib: a review of its use as second-line treatment in adults with advanced non-small-cell lung cancer of adenocarcinoma histology. Targ Oncol 2015; 10: 303–310.

European Medicines Agency. Lynparza: CHMP assessment report, www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/003726/WC500180154.pdf (2014, accessed 23 October 2014).

Kim G Ison G McKee AE . FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res 2015; 21: 4257–4261.

Morikawa A Henry NL . Palbociclib for the treatment of estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res 2015; 21: 3591–3596.

IBRANCE^® (palbociclib) [prescribing information]. New York: Pfizer Inc., 2015, http://labeling.pfizer.com/ShowLabeling.aspx?id=2191 (accessed 22 February 2016).

Heath EI Chiorean EG Sweeney CJ . A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther 2010; 88: 818–823.

Deng Y Sychterz C Suttle AB . Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica 2013; 43: 443–453.

Cortes JE Kantarjian H Shah NP . Ponatinib in refractory Philadelphia chromosome–positive leukemias. N Engl J Med 2012; 367: 2075–2088.

Shamroe CL Comeau JM . Ponatinib: a new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia. Ann Pharmacother 2013; 47: 1540–1546.

Crona DJ Keisler MD Walko CM . Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors. Ann Pharmacother 2013; 47: 1685–1696.

Rey JB Launay-Vacher V Tournigand C . Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists. Targ Oncol 2015; 10: 199–213.

Shilling AD Nedza FM Emm T . Metabolism, excretion, and pharmacokinetics of [14C] INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos 2010; 38: 2023–2031.

Swaim SJ . Ruxolitinib for the treatment of primary myelofibrosis. Am J Health Syst Pharm 2014; 71: 453–462.

European Medicines Agency. Odomzo: CHMP assessment report, www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/002839/WC500192972.pdf (2015, accessed 25 June 2015).

Zollinger M Lozac’h F Hurh E . Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother Pharmacol 2014; 74: 63–75.

Kane RC Farrell AT Saber H . Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006; 12: 7271–7278.

Rini BI . Sorafenib. Expert Opin Pharmacother 2006; 7: 453–461.

Minami H Kawada K Ebi H . Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 2008; 99: 1492–1498.

Adams VR Leggas M . Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007; 29: 1338–1353.

Speed B Bu HZ Pool WF . Pharmacokinetics, distribution, and metabolism of [14C] sunitinib in rats, monkeys, and humans. Drug Metab Dispos 2012; 40: 539–555.

Bisht S Feldmann G Brossart P . Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors. Expert Opin Drug Metab Toxicol 2013; 9: 777–788.

Kassir N Mouksassi M Cox DS . Population pharmacokinetics (PK) of trametinib (GSK1120212), a MEK inhibitor, in subjects with cancer [abstract PII-48]. Clin Pharmacol Ther 2013; 93: S69–S69.

Ho MY Morris MJ Pirhalla JL . Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers. Xenobiotica 2014; 44: 352–368.

Chung C Reilly S . Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma. Am J Health Syst Pharm 2015; 72: 101–110.

Zhang L Li S Zhang Y . Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther 2011; 33: 315–327.

Martin P Oliver S Kennedy SJ . Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther 2012; 34: 221–237.

Cooper MR Yi SY Alghamdi W . Vandetanib for the treatment of medullary thyroid carcinoma. Ann Pharmacother 2014; 48: 387–394.

Kim G McKee AE Ning YM . FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res 2014; 20: 4994–5000.

Goldinger SM Rinderknecht J Dummer R . A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. Pharmacol Res Perspect 2015; 3: e00113–e00113. DOI: 10.1002/prp2.113.

Graham RA Lum BL Morrison G . A single dose mass balance study of the hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Dispos 2011; 39: 1460–1467.

Poggi L Kolesar JM . Vismodegib for the treatment of basal cell skin cancer. Am J Health Syst Pharm 2013; 70: 1033–1038.

Proctor AE Thompson LA O’Bryant CL . Vismodegib: an inhibitor of the hedgehog signaling pathway in the treatment of basal cell carcinoma. Ann Pharmacother 2014; 48: 99–106.

Judson I Ma P Peng B . Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005; 55: 379–386.

van Erp NP Gelderblom H Guchlaar HJ . Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009; 35: 692–706.

Duckett DR Cameron MD . Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol 2010; 6: 1175–1193.

Abbas R Chalon S Leister C . Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol 2013; 71: 123–132.

DeSantis CE Lin CC Mariotto AB . Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64: 252–271.

Pessi MA Zilembo N Haspinger ER . Targeted therapy-induced diarrhea: a review of the literature. Crit Rev Oncol Hematol 2014; 90: 165–179.

Lester J . Safe handling and administration considerations of oral anticancer agents in the clinical and home setting. Clin J Oncol Nurs 2012; 16: E192–197.

Held K Ryan R Champion JM . Caregiver survey results related to handling of oral chemotherapy for pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2013; 35: e249–e253.

Roop JC Wu H-S . Current practice patterns for oral chemotherapy: results of a national survey. Oncol Nurs Forum 2014; 41: 185–194.

Gilani S Giridharan S . Is it safe for pregnant health-care professionals to handle cytotoxic drugs? A review of the literature and recommendations. Ecancermedicalscience 2014; 8: 418–418.

Wong SF Mirshahidi H . Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners. Ann Pharmacother 2011; 45: 787–797.

Dorris JR 3rd Jones S . Everolimus in breast cancer: the role of the pharmacist. Ann Pharmacother 2014; 48: 1194–1201.

Abbott R Edwards S Whelan M . Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada. J Oncol Pharm Pract 2014; 20: 29–39.